Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants With Overweight or Obesity

NCT06132841 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06132841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants With Overweight or Obesity
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 13, 2023
Completion date
March 7, 2026
Enrollment
104 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants